02:22 , Jan 9, 2016 |  BC Extra  |  Financial News

Brandon Capital taps Read for Bay Area presence

Australian venture firm Brandon Capital hired J. Leighton Read as a venture partner and head of the firm's newly opened office in Palo Alto, Calif. Read was most recently a managing member at Alloy Ventures,...
07:00 , Jul 27, 2009 |  BioCentury  |  Regulation

FluMist ramps up fast

If pandemic H1N1 influenza hits the U.S. hard this fall, the nation's first line of defense could be a live attenuated influenza vaccine based on FluMist manufactured by the MedImmune Inc. subsidiary of AstraZeneca plc...
07:00 , Apr 30, 2007 |  BioCentury  |  Strategy

Scale was elusive

MedImmune Inc. is going away in what can only be called a blaze of glory - a $15.6 billion takeout by AstraZeneca plc . The deal price is about a 53% premium to MEDI's valuation...
07:00 , Apr 30, 2007 |  BioCentury  |  Strategy

MedImmune chronicles

MedImmune chronicles Since late 2000, MedImmune's stock performance has lagged its peers, as gauged by a price-weighted index consisting of Amgen (AMGN), Biogen Idec (BIIB), Genentech (DNA), Genzyme (GENZ) and Gilead (GILD). In fact, prior...
08:00 , Mar 28, 2005 |  BioCentury  |  Product Development

Third World solutions

For years, the prevailing belief among international and non-profit organizations has been that vaccines for developing countries should be given away or provided at pennies per dose. This view often has been actively hostile to...
07:00 , Oct 11, 2004 |  BioCentury  |  Politics, Policy & Law

Fluvirin: Maybe a silver lining

Senior U.S. officials offered little hope at week's end that any of Chiron Corp. 's Fluvirin influenza vaccine will reach the market during the current flu season. Barring a complete reversal of the positions taken...
08:00 , Mar 22, 2004 |  BC Week In Review  |  Company News

Vaxin management update

Vaxin Inc. , Birmingham, Ala.   Business: Infectious   Hired: Francis Cano as chairman and CEO, formerly president and COO of Aviron  ...
08:00 , Mar 8, 2004 |  BioCentury  |  Product Development

The FluMist chill

The FluMist chill MEDI's stock price tracked with selected FluMist news A 12/3/01 MEDI announces plans to acquire Aviron , including FluMist productB 08/27/02 MEDI replies to FDA complete response letter for FluMistC 10/25/02 MEDI...
08:00 , Mar 8, 2004 |  BioCentury  |  Product Development

Back to Square III

When MedImmune Inc. acquired Aviron in late 2001 for $1.5 billion in stock, the company assumed that Aviron's FluMist influenza vaccine would garner $500 million in sales within three years of launch and $1 billion...
08:00 , Feb 16, 2004 |  BioCentury  |  Finance

Ebb & Flow

The new rules separating investment banking and sellside analysis don't seem to have affected research coverage. Analysts at the banks that took the recent class of biotech IPOs public have not only delivered on coverage,...